Search 177 catalogue identities by name or alias. Find recorded vendor packages, markets and cited reference notes in one place.
15 entries have a reviewed selection of primary sources. Other entries are marked as awaiting review. A source review covers the stated claims; it does not certify a vendor, a batch, clinical efficacy or suitability for human use.
Categories such as “Healing” and “Weight Loss” are catalogue navigation labels, not evidence of an effect or an approved use. Similar names can identify different compounds; source notes flag reviewed distinctions.
Tesofensine Capsules is a catalogue entry whose compound-specific reference review has not yet been completed.
Testagen is a catalogue entry whose compound-specific reference review has not yet been completed.
Thymalin is a catalogue entry whose compound-specific reference review has not yet been completed.
Thymogen is a catalogue entry whose compound-specific reference review has not yet been completed.
Aliases: ta-1 · thymalfasin
Thymosin Alpha-1 is a catalogue entry whose compound-specific reference review has not yet been completed.
Full-length thymosin beta-4 is a 43-amino-acid peptide. Its chemical identity differs from the short fragment characterized as TB-500 in the cited analytical literature.
Aliases: GLP-2T · tirz
Tirzepatide acts at GIP and GLP-1 receptors and is the active substance in the EU-authorized prescription medicine Mounjaro. Its medicinal-product assessment is separate from a supplier’s research catalogue listing.
Tirzepatide Nasal Spray is a catalogue entry whose compound-specific reference review has not yet been completed.
Tirzepatide Oral Spray is a catalogue entry whose compound-specific reference review has not yet been completed.
TRH (Protirelin) is a catalogue entry whose compound-specific reference review has not yet been completed.
Tripeptide-29 is a catalogue entry whose compound-specific reference review has not yet been completed.
Triptorelin is a catalogue entry whose compound-specific reference review has not yet been completed.
Vesugen is a catalogue entry whose compound-specific reference review has not yet been completed.
Vialox (Pentapeptide-3V) is a catalogue entry whose compound-specific reference review has not yet been completed.
Vilon is a catalogue entry whose compound-specific reference review has not yet been completed.
VIP is a catalogue entry whose compound-specific reference review has not yet been completed.
YK-11 is a catalogue entry whose compound-specific reference review has not yet been completed.